pyridoxine has been researched along with Hyperoxaluria in 29 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
Hyperoxaluria: Excretion of an excessive amount of OXALATES in the urine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the effects of dietary manipulation and pyridoxine medical management for idiopathic hyperoxaluria in patients with nephrolithiasis." | 7.77 | Pyridoxine and dietary counseling for the management of idiopathic hyperoxaluria in stone-forming patients. ( Kriedberg, C; Miyaoka, R; Moeding, A; Monga, M; Ortiz-Alvarado, O; Stessman, M, 2011) |
| "We studied the long-term effects of orthophosphate and pyridoxine therapy in 25 patients with primary hyperoxaluria who were treated for an average of 10 years (range, 0." | 7.69 | Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. ( Bergstralh, EJ; Eickholt, JT; Milliner, DS; Smith, LH; Wilson, DM, 1994) |
| "Plasma pyridoxine metabolites in plasma and 4-pyridoxic acid excretions in urine were measured in normal subjects, in 7 patients with type-1 hyperoxaluria and in 8 patients with mild metabolic hyperoxaluria, while receiving various doses of pyridoxine." | 7.68 | Metabolism of pyridoxine in mild metabolic hyperoxaluria and primary hyperoxaluria (type 1). ( Edwards, P; Rose, GA, 1991) |
| "Pyridoxine in doses of 250-500 mg daily by mouth was administered to 12 patients suffering from recurrent calcium oxalate renal calculi and idiopathic hyperoxaluria." | 7.67 | Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones. ( Ayiomamitis, A; Grass, L; Mitwalli, A; Oreopoulos, DG, 1988) |
| "Three cases of mild metabolic hyperoxaluria (with glycollaturia) are described." | 5.27 | Mild metabolic hyperoxaluria and its response to pyridoxine. ( Gill, HS; Rose, GA, 1986) |
| "To examine the effects of dietary manipulation and pyridoxine medical management for idiopathic hyperoxaluria in patients with nephrolithiasis." | 3.77 | Pyridoxine and dietary counseling for the management of idiopathic hyperoxaluria in stone-forming patients. ( Kriedberg, C; Miyaoka, R; Moeding, A; Monga, M; Ortiz-Alvarado, O; Stessman, M, 2011) |
| "We studied the long-term effects of orthophosphate and pyridoxine therapy in 25 patients with primary hyperoxaluria who were treated for an average of 10 years (range, 0." | 3.69 | Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. ( Bergstralh, EJ; Eickholt, JT; Milliner, DS; Smith, LH; Wilson, DM, 1994) |
| "Plasma pyridoxine metabolites in plasma and 4-pyridoxic acid excretions in urine were measured in normal subjects, in 7 patients with type-1 hyperoxaluria and in 8 patients with mild metabolic hyperoxaluria, while receiving various doses of pyridoxine." | 3.68 | Metabolism of pyridoxine in mild metabolic hyperoxaluria and primary hyperoxaluria (type 1). ( Edwards, P; Rose, GA, 1991) |
| "Pyridoxine in doses of 250-500 mg daily by mouth was administered to 12 patients suffering from recurrent calcium oxalate renal calculi and idiopathic hyperoxaluria." | 3.67 | Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones. ( Ayiomamitis, A; Grass, L; Mitwalli, A; Oreopoulos, DG, 1988) |
| "Pyridoxine (vitamin B6), given to patients with primary hyperoxaluria of type I, generally leads to a decrease in urinary excretion of oxalate owing to stimulation of conversion of glyoxylate to glycine instead of oxalate." | 3.67 | [Pyridoxine can normalize oxaluria in idiopathic renal lithiasis]. ( Burckhardt, P; Jacquet, AF; Jaeger, P; Portmann, L, 1986) |
| "Whether meat protein intake affects oxaluria, however, remains controversial in healthy subjects and in stone formers." | 2.70 | Sensitivity to meat protein intake and hyperoxaluria in idiopathic calcium stone formers. ( Casez, JP; Drouve, U; Jaeger, P; Kälin, A; Nguyen, QV, 2001) |
| "Primary hyperoxaluria type I is a metabolic disorder caused by the deficiency of the peroxisomal alanine:glyoxylate aminotransferase." | 2.38 | Primary hyperoxaluria type I. ( Brodehl, J; Latta, K, 1990) |
| "Primary hyperoxaluria type 1 (PH1) is an inborn error of glyoxylate metabolism, characterized by increased endogenous oxalate production." | 1.62 | Endogenous Oxalate Production in Primary Hyperoxaluria Type 1 Patients. ( Garrelfs, SF; Groothoff, JW; Oosterveld, MJS; Peters-Sengers, H; Schierbeek, H; van den Akker, CHP; van Goudoever, JB; van Harskamp, D; Wanders, RJA; Wijburg, FA, 2021) |
| "Primary hyperoxalurias are rare recessive inherited inborn errors of glyoxylate metabolism." | 1.37 | [Primary hyperoxaluria]. ( Bacchetta, J; Bertholet-Thomas, A; Cochat, P; Fargue, S; Harambat, J; Sabot, JF, 2011) |
| "Treatment with lupeol and lupeol linoleate reduced the extent of tubular damage as evidenced from reduced enzymuria and minimized the excretion of stone forming constituents." | 1.31 | Evaluation of the effect of triterpenes on urinary risk factors of stone formation in pyridoxine deficient hyperoxaluric rats. ( Lenin, M; Varalakshmi, P; Vidya, L, 2002) |
| "Primary hyperoxaluria type I (PH I) is characterized by an excessive endogenous production and excretion of oxalic and glycolic acid." | 1.28 | Vitamin B6 resistant primary hyperoxaluria type I. Report of 5 cases. ( Donckerwolcke, RA; Streefland, M, 1989) |
| "Whewellite was the major component of calculi in all cases but the stones exhibited a peculiar morphological arrangement, with multiple small indentations and a fine mamillary structure." | 1.27 | Piridoxilate-induced calcium oxalate calculi: a new drug-induced metabolic nephrolithiasis. ( Daudon, M; Jungers, P; Normand, M; Petit, C; Reveillaud, RJ, 1987) |
| "Three cases of mild metabolic hyperoxaluria (with glycollaturia) are described." | 1.27 | Mild metabolic hyperoxaluria and its response to pyridoxine. ( Gill, HS; Rose, GA, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (34.48) | 18.7374 |
| 1990's | 9 (31.03) | 18.2507 |
| 2000's | 5 (17.24) | 29.6817 |
| 2010's | 4 (13.79) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Garrelfs, SF | 1 |
| van Harskamp, D | 1 |
| Peters-Sengers, H | 1 |
| van den Akker, CHP | 1 |
| Wanders, RJA | 1 |
| Wijburg, FA | 1 |
| van Goudoever, JB | 1 |
| Groothoff, JW | 1 |
| Schierbeek, H | 1 |
| Oosterveld, MJS | 1 |
| Assimos, DG | 1 |
| Ortiz-Alvarado, O | 1 |
| Miyaoka, R | 1 |
| Kriedberg, C | 1 |
| Moeding, A | 1 |
| Stessman, M | 1 |
| Monga, M | 1 |
| Punjabi, OS | 1 |
| Riaz, K | 1 |
| Mets, MB | 1 |
| Cochat, P | 1 |
| Fargue, S | 1 |
| Bacchetta, J | 1 |
| Bertholet-Thomas, A | 1 |
| Sabot, JF | 1 |
| Harambat, J | 1 |
| Vidya, L | 2 |
| Lenin, M | 1 |
| Varalakshmi, P | 2 |
| Kaelin, A | 1 |
| Casez, JP | 2 |
| Jaeger, P | 3 |
| Gaines, L | 1 |
| Waibel, KH | 1 |
| Milliner, DS | 1 |
| Eickholt, JT | 1 |
| Bergstralh, EJ | 1 |
| Wilson, DM | 1 |
| Smith, LH | 1 |
| Malini, MM | 1 |
| Nguyen, QV | 1 |
| Kälin, A | 1 |
| Drouve, U | 1 |
| Tanase, S | 1 |
| Morino, Y | 1 |
| Costello, JF | 1 |
| Sadovnic, MC | 1 |
| Smith, M | 1 |
| Stolarski, C | 1 |
| Shah, GM | 1 |
| Ross, EA | 1 |
| Sabo, A | 1 |
| Pichon, M | 1 |
| Reynolds, RD | 1 |
| Bhagavan, H | 1 |
| Edwards, P | 2 |
| Rose, GA | 3 |
| Nemat, S | 1 |
| Latta, K | 1 |
| Brodehl, J | 1 |
| Nath, R | 2 |
| Thind, SK | 2 |
| Murthy, MS | 1 |
| Farooqui, S | 1 |
| Gupta, R | 1 |
| Koul, HK | 1 |
| Watts, RW | 2 |
| Streefland, M | 1 |
| Donckerwolcke, RA | 1 |
| Wanders, RJ | 1 |
| van Roermund, CW | 1 |
| Jurriaans, S | 1 |
| Schutgens, RB | 1 |
| Tager, JM | 1 |
| van den Bosch, H | 1 |
| Wolff, ED | 1 |
| Przyrembel, H | 1 |
| Berger, R | 1 |
| Schaaphok, FG | 1 |
| Mitwalli, A | 1 |
| Ayiomamitis, A | 1 |
| Grass, L | 1 |
| Oreopoulos, DG | 1 |
| Gulati, S | 1 |
| Narula, R | 1 |
| Sadhna, S | 1 |
| Sidhu, H | 1 |
| Wangoo, D | 1 |
| Yano, S | 1 |
| Yoshino, M | 1 |
| Nishiyori, A | 1 |
| Nakao, M | 1 |
| Matsumoto, T | 1 |
| Ito, Y | 1 |
| Yamashita, F | 1 |
| Shimada, A | 1 |
| Inokuchi, T | 1 |
| Morgan, SH | 1 |
| Purkiss, P | 1 |
| Mansell, MA | 1 |
| Baker, LR | 1 |
| Brown, CB | 1 |
| Daudon, M | 1 |
| Reveillaud, RJ | 1 |
| Normand, M | 1 |
| Petit, C | 1 |
| Jungers, P | 1 |
| Amato, M | 1 |
| Donzelli, S | 1 |
| Lombardi, M | 1 |
| Salvadori, M | 1 |
| Carini, M | 1 |
| Selli, C | 1 |
| Caudarella, R | 1 |
| Portmann, L | 1 |
| Jacquet, AF | 1 |
| Burckhardt, P | 1 |
| Gill, HS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Outcomes of Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in the Early Treatment of Sepsis.[NCT03422159] | Phase 2 | 140 participants (Actual) | Interventional | 2018-02-05 | Completed | ||
| Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria[NCT00280215] | Phase 3 | 0 participants (Actual) | Interventional | 2007-12-31 | Withdrawn (stopped due to Inadequate number of patients, lack of funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as the day 4 post-randomization SOFA score minus the initial SOFA score. The Sequential Organ Failure Assessment (SOFA) Score is a mortality prediction score that is based on the degree of dysfunction of six organ systems. The score is calculated on admission and every 24 hours until discharge using the worst parameters measured during the prior 24 hours SOFA score ranges from 0 (no organ dysfunction) to 24 (highest possible score / organ dysfunction). (NCT03422159)
Timeframe: 4 days post-randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Arm | 2.9 |
| Placebo Arm | 1.93 |
Time from admitting to discharge of hospital stay. (NCT03422159)
Timeframe: From admission to the hospital until final discharge, up to 28 days.
| Intervention | Days (Mean) |
|---|---|
| Treatment Arm | 11.5 |
| Placebo Arm | 11 |
In-hospital mortality rate. (NCT03422159)
Timeframe: Survival until hospital discharge, up to 28 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm | 11 |
| Placebo Arm | 13 |
Time from admitting to ICU to discharge. (NCT03422159)
Timeframe: From admission to the ICU until final discharge from the ICU, up to an average of 7 days.
| Intervention | days (Mean) |
|---|---|
| Treatment Arm | 4.76 |
| Placebo Arm | 4.66 |
ICU mortality rate (NCT03422159)
Timeframe: From admission to hospital until final discharge from the ICU, up to 28 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm | 6 |
| Placebo Arm | 10 |
PCT at 96 hours minus initial PCT, divided by the initial PCT multiplied by 100. (NCT03422159)
Timeframe: 4 days post-randomization
| Intervention | Percent (Mean) |
|---|---|
| Treatment Arm | 63 |
| Placebo Arm | 58 |
Defined as the time from starting the active treatment/placebo to discontinuation of all pressors. (NCT03422159)
Timeframe: From start of vasopressor medication to final discontinuation of vasopressor medication, up to 7 days.
| Intervention | hours (Mean) |
|---|---|
| HAT Treatment | 27 |
| Comparator | 53 |
Number of days alive and off of the ventilator at day 28. (NCT03422159)
Timeframe: 28 Days post-randomization
| Intervention | Days (Mean) |
|---|---|
| Treatment Arm | 22 |
| Placebo Arm | 22.4 |
2 reviews available for pyridoxine and Hyperoxaluria
| Article | Year |
|---|---|
Primary hyperoxaluria type I.
Topics: Age Factors; Alanine Transaminase; Child; Combined Modality Therapy; Female; Genes, Recessive; Human | 1990 |
Role of pyridoxine in oxalate metabolism.
Topics: Animals; Gonadal Steroid Hormones; Hyperoxaluria; Intestinal Absorption; Kidney; Liver; Male; Oxalat | 1990 |
1 trial available for pyridoxine and Hyperoxaluria
| Article | Year |
|---|---|
Sensitivity to meat protein intake and hyperoxaluria in idiopathic calcium stone formers.
Topics: Adult; Calcium; Diet, Protein-Restricted; Dietary Proteins; Glycolates; Humans; Hyperoxaluria; Kidne | 2001 |
26 other studies available for pyridoxine and Hyperoxaluria
| Article | Year |
|---|---|
Endogenous Oxalate Production in Primary Hyperoxaluria Type 1 Patients.
Topics: Glycine; Glycolates; Glyoxylates; Humans; Hyperoxaluria; Hyperoxaluria, Primary; Oxalates; Pyridoxin | 2021 |
Re: Pyridoxamine and Pyridoxal are More Effective than Pyridoxine in Rescuing Folding-Defective Variants of Human Alanine:Glyoxylate Aminotransferase Causing Primary Hyperoxaluria Type I.
Topics: Alanine; Humans; Hyperoxaluria; Hyperoxaluria, Primary; Pyridoxal; Pyridoxamine; Pyridoxine | 2016 |
Pyridoxine and dietary counseling for the management of idiopathic hyperoxaluria in stone-forming patients.
Topics: Combined Modality Therapy; Directive Counseling; Female; Humans; Hyperoxaluria; Longitudinal Studies | 2011 |
Crystalline retinopathy in primary hyperoxaluria.
Topics: Electroretinography; Humans; Hyperoxaluria; Hyperoxaluria, Primary; Infant; Liver Transplantation; M | 2011 |
[Primary hyperoxaluria].
Topics: Alanine Transaminase; Disease Progression; Genotype; Humans; Hyperoxaluria; Hyperoxaluria, Primary; | 2011 |
Evaluation of the effect of triterpenes on urinary risk factors of stone formation in pyridoxine deficient hyperoxaluric rats.
Topics: Acetylglucosaminidase; Alkaline Phosphatase; Animals; Calcium; Calcium Oxalate; gamma-Glutamyltransf | 2002 |
Vitamin B6 metabolites in idiopathic calcium stone formers: no evidence for a link to hyperoxaluria.
Topics: Adult; Aged; Case-Control Studies; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Hu | 2004 |
Calcium oxalate crystalluria.
Topics: Adult; Calcium Oxalate; Diagnosis, Differential; Ethanol; Ethylene Glycol; Humans; Hyperoxaluria; Ma | 2007 |
Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria.
Topics: Actuarial Analysis; Adolescent; Adult; Calcium Oxalate; Child; Child, Preschool; Female; Follow-Up S | 1994 |
Effect of pentacyclic triterpenes on oxalate-induced changes in rat erythrocytes.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Erythrocytes; Hyperoxaluria; | 2000 |
[Vitamin B6 dependency syndrome].
Topics: Amino Acid Metabolism, Inborn Errors; Aspartate Aminotransferases; Cystathionine; Homocystinuria; Hu | 1992 |
Effect of vitamin B6 supplementation on plasma oxalate and oxalate removal rate in hemodialysis patients.
Topics: Alanine Transaminase; Creatinine; Humans; Hyperoxaluria; Kidney Calculi; Kidney Failure, Chronic; Ox | 1992 |
Effects of ascorbic acid and pyridoxine supplementation on oxalate metabolism in peritoneal dialysis patients.
Topics: Aged; Ascorbic Acid; Humans; Hyperoxaluria; Kidney Failure, Chronic; Male; Middle Aged; Oxalates; Pe | 1992 |
Metabolism of pyridoxine in mild metabolic hyperoxaluria and primary hyperoxaluria (type 1).
Topics: Chromatography, High Pressure Liquid; Humans; Hyperoxaluria; Hyperoxaluria, Primary; Pyridoxic Acid; | 1991 |
Effects of oral pyridoxine upon plasma and 24-hour urinary oxalate levels in normal subjects and stone formers with idiopathic hypercalciuria.
Topics: Calcium; Female; Humans; Hyperoxaluria; Male; Oxalates; Pyridoxine; Urinary Calculi | 1990 |
Treatment of renal failure in the primary hyperoxalurias.
Topics: Adult; Calcium Oxalate; Child; Combined Modality Therapy; Humans; Hyperoxaluria; Kidney Calculi; Kid | 1990 |
Vitamin B6 resistant primary hyperoxaluria type I. Report of 5 cases.
Topics: Child; Child, Preschool; Drug Resistance; Female; Follow-Up Studies; Humans; Hyperoxaluria; Hyperoxa | 1989 |
Diversity in residual alanine glyoxylate aminotransferase activity in hyperoxaluria type I: correlation with pyridoxine responsiveness.
Topics: Alanine Transaminase; Glycolates; Humans; Hyperoxaluria; Liver; Oxalates; Oxalic Acid; Pyridoxine; T | 1988 |
Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones.
Topics: Adult; Aged; Female; Humans; Hyperoxaluria; Kidney Calculi; Male; Middle Aged; Oxalates; Pyridoxine | 1988 |
Effect of magnesium and pyridoxine supplementation on glycolate induced hyperoxaluria in male albino rats.
Topics: Animals; Hyperoxaluria; Magnesium; Male; Pyridoxine; Rats; Rats, Inbred Strains; Urinary Calculi | 1988 |
Hyperoxaluria type I: therapeutic effects of pyridoxine hydrochloride and inheritance patterns of the disease in a family.
Topics: Child; Child, Preschool; Female; Humans; Hyperoxaluria; Hyperoxaluria, Primary; Male; Pedigree; Pyri | 1988 |
Timing of renal transplantation in the management of pyridoxine-resistant type I primary hyperoxaluria.
Topics: Adolescent; Adult; Drug Resistance; Female; Humans; Hyperoxaluria; Hyperoxaluria, Primary; Kidney Fa | 1988 |
Piridoxilate-induced calcium oxalate calculi: a new drug-induced metabolic nephrolithiasis.
Topics: Adult; Aged; Calcium Oxalate; Coronary Disease; Female; Humans; Hyperoxaluria; Kidney Calculi; Male; | 1987 |
Primary hyperoxaluria: effect of treatment with vitamin B6 and shock waves.
Topics: Adult; HLA Antigens; Humans; Hyperoxaluria; Hyperoxaluria, Primary; Kidney Calculi; Lithotripsy; Mal | 1987 |
[Pyridoxine can normalize oxaluria in idiopathic renal lithiasis].
Topics: Adult; Drug Evaluation; Female; Humans; Hyperoxaluria; Hyperoxaluria, Primary; Jejunoileal Bypass; K | 1986 |
Mild metabolic hyperoxaluria and its response to pyridoxine.
Topics: Adult; Drug Administration Schedule; Humans; Hyperoxaluria; Kidney Calculi; Male; Middle Aged; Pyrid | 1986 |